Hepatocellular carcinoma

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Jan. 21, 2021

Language: Английский

---

Hepatocellular Carcinoma

New England Journal of Medicine, Journal Year: 2019, Volume and Issue: 380(15), P. 1450 - 1462

Published: April 10, 2019

Primary liver cancer is the fourth most common tumor worldwide. Hepatocellular carcinoma occurs mainly in context of cirrhosis, hepatitis B or C virus infection, nonalcoholic steatohepatitis. Underlying disease limits therapeutic efficacy.

Language: Английский

---

Molecular therapies and precision medicine for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(10), P. 599 - 616

Published: July 30, 2018

Language: Английский

---

Epidemiology and Management of Hepatocellular Carcinoma

Gastroenterology, Journal Year: 2018, Volume and Issue: 156(2), P. 477 - 491.e1

Published: Oct. 24, 2018

Language: Английский

---

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Cell, Journal Year: 2021, Volume and Issue: 184(10), P. 2537 - 2564

Published: May 1, 2021

Language: Английский

---

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 19(3), P. 151 - 172

Published: Nov. 11, 2021

Language: Английский

---

Advances in immunotherapy for hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 18(8), P. 525 - 543

Published: April 13, 2021

Hepatocellular carcinoma (HCC) is a prevalent disease with progression that modulated by the immune system. Systemic therapy used in advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy checkpoint has shown strong anti-tumour activity subset patients combination anti-PDL1 antibody atezolizumab VEGF-neutralizing bevacizumab or will soon become standard care as first-line for HCC, whereas anti-PD1 agents nivolumab pembrolizumab are after TKIs several regions. Other strategies such adoptive T-cell transfer, vaccination virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges HCC immunotherapy discovery validation predictive biomarkers, advancing treatment to earlier stages disease, applying liver dysfunction more effective combinatorial sequential approaches. Combinations other systemic local treatments perceived most promising opportunities some already under evaluation large-scale trials. This Review provides up-to-date information on best use currently available immunotherapies therapeutic development. Immunotherapeutic interventions might be tools hepatocellular carcinoma. carcinoma, mechanisms response resistance,

Language: Английский

---

The immunology of hepatocellular carcinoma

Nature Immunology, Journal Year: 2018, Volume and Issue: 19(3), P. 222 - 232

Published: Jan. 26, 2018

Language: Английский

---

Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

Nature, Journal Year: 2019, Volume and Issue: 567(7747), P. 257 - 261

Published: Feb. 27, 2019

Language: Английский

---

Tumour evolution in hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2019, Volume and Issue: 17(3), P. 139 - 152

Published: Dec. 2, 2019

Language: Английский

---